ZUG, Switzerland - Wednesday, 16. September 2026
Positive topline results showed that Restylane Volyme (known as Restylane Contour in the U.S.) was highly effective in the correction of moderate-to-severe temple hollowing, with high responder rates maintained through Month 121
Restylane Volyme was well tolerated, with no incidences of granulomas. Patient and investigator satisfaction were also high1
These data support Galderma’s aim to expand the availability of the Restylane portfolio in China – a market undergoing significant expansion, and further strengthen Restylane’s vast clinical evidence base2,3
(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patients in China.1 The study met its primary endpoint, demonstrating the effectiveness and safety of Restylane Volyme versus a no-treatment control, while also achieving high patient and investigator satisfaction.1 These data further reinforce Galderma's ambition to expand its Restylane hyaluronic acid (HA) injectables portfolio in China, one of the world's fastest-growing aesthetics markets, through evidence generation that supports broader patient access and additional treatment areas.1-3
Powered by diverse NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.1,4-8 Restylane Volyme is a moderately soft and flexible gel made with OBT that distributes within the tissue to offer natural-looking results, helping to soften temple hollowing, restore facial balance, and create a refreshed appearance.1,4,9 With a dual-layer patent-pending technique leveraging both needle and cannula, Restylane Volyme enables healthcare professionals to provide precise, customized, and safe product placement in line with each patient’s aesthetic goals10-12
The volume of the temples can diminish with age, which can disrupt facial balance and harmony, and contribute to a tired, sunken, and aged appearance.12-14 These facial changes can be accelerated in people undergoing medication-driven weight loss, a phenomenon which has increased rapidly in recent years.12-14 Following the launch of Restylane Volyme in China for the treatment of the mid-face region, this study provides new evidence supporting its effectiveness and safety for correction of temple hollowing, in a market where there are currently limited options.1
“Temple hollowing is a common concern among patients seeking facial rejuvenation, particularly for those experiencing medication-driven weight loss, yet treatment options in China remain limited. These results demonstrate that Restylane Volyme can provide effective, natural-looking correction with high levels of patient satisfaction and a robust safety profile. As demand for individualized aesthetic treatments continues to grow in China, expanding the range of evidence-based solutions available will be increasingly important.”
PROF. ZHAO HONGYI
STUDY PRINCIPAL INVESTIGATOR,
DIRECTOR & CHIEF OF THE DEPARTMENT OF PLASTIC SURGERY, BEIJING HOSPITAL, CHINA
In this randomized, evaluator-blinded study, 162 adults were recruited across six sites in China and were split 2:1 into two groups; the Restylane Volyme treatment group or the no treatment control group.1 Results showed that for patients in the Restylane Volyme group:
Strong effectiveness
94.4% of patients demonstrated at least 1-grade improvement in temple hollowing, from baseline, in both temples at Month 6 after last treatment, compared to just 2.0% in the control group at Month 6 after baseline.1
Blinded-evaluator Galderma Temple Volume Deficit Scale responder rates remained high through Month 121
91.3% of patients showed improvement on the Global Aesthetic Improvement Scale for both temples through Month 12, according to the treating investigator1
High satisfaction
Patient satisfaction was high at Month 3 and remained consistently high, with more than 84% of patients satisfied with both the natural look and natural feel of their temples through Month 121
More than 90% said they would recommend the treatment to a friend, and over 86% would have the treatment again1
Half of the participants felt comfortable returning to social engagement within 24 hours after initial treatment1
Robust safety
Restylane Volyme was generally well tolerated, with no treatment-related serious adverse events and no granulomas1
“These positive topline results further strengthen the clinical evidence supporting Restylane Volyme and mark an important step in our strategy to expand the Restylane portfolio in China. As one of the world’s fastest-growing aesthetics markets, China presents a significant opportunity to address evolving patient needs with science-backed, differentiated solutions. This study supports our ambition to broaden the indications available to practitioners and patients, while reinforcing Galderma’s leadership in Injectable Aesthetics through continued investment in innovation and clinical research.”
BALDO SCASSELLATI SFORZOLINI, M.D., PH.D.
GLOBAL HEAD OF R&D
GALDERMA
With over 30 years of innovation and more than 77 million treatments administered worldwide, the Restylane portfolio offers a versatile range of HA gels that remain highly relevant in responding to today’s most significant aesthetic trends and needs.15-16 China is one of the fastest growing aesthetics markets worldwide and HA fillers are among the top 10 most-sold aesthetics products.2,3 This study highlights Galderma’s commitment to expand the availability of its Restylane portfolio to more patients and practitioners in China and exemplifies its continuing expansion in a growing and strategically significant market.
About the Restylane portfolio
Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.17-19 Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.5,20,21 Powered by NASHA®, NASHA HD™, and OBT™ technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.4,6-8 Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results. 18,22,23 Approved indications vary by market.
About Galderma
Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body’s largest organ – the skin – meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: www.galderma.com.
References
Galderma. Data on file. 43CH2401
Deloitte. China Aesthetic Medicine Outlook Report. Accessed September 2026. Available online.
Grand View Horizon. China Aesthetic Medicine Market Size & Outlook, 2026-2033. Accessed September 2026. Available online
Galderma. Data on file. MA-56724. 2023. Global rheology data (xStrain and G´ including Restylane SHAYPE).
Galderma. Data on file. MA-58650. Degree of modification of HA fillers.
Nikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. J Drugs Dermatol. 2024;23(4):255–261. doi: 10.36849/JDD.8145.
Öhrlund Å, et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance. J Drugs Dermatol. 2024;23(1):1332–1336. doi: 10.36849/JDD.7648.
Belmontesi M, et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus. J Drugs Dermatol. 2018;17(1):83–88.
Talarico S et al. High Patient Satisfaction of a Hyaluronic Acid Filler Producing Enduring Full-Facial Volume Restoration: An 18-Month Open Multicenter Study. Dermatol Surg. 2015;41(12):1361-9. doi: 10.1097/DSS.0000000000000549
Restylane® Volyme. IFU. Available online. Accessed September 2026
Galderma Laboratories, L.P. Data on file. MA-63365 Study Report. 2025
Galderma. Data on file. Restylane Contour temple investigator closeout meeting executive summary. 2025
Humphrey CD & Lawrence AC. Implications of Ozempic and other GLP-1 receptor agonists for facial plastic surgeons. Facial Plast Surg, 2023;39:719-73. doi: 10.1055/a-2148-6321
Tay JQ. Ozempic face: A new challenge for facial plastic surgeons. JPRAS.2023;81-97-98. doi: 10.1016/j.bjps.2023.04.057
Galderma. Data on file. MA-57232 [Updated]. 77 Million treated.
Galderma. Data on file. MA-55607. Restylane® 27 years data publications analysis
Restylane® EU Instructions for Use. July 2026.
Di Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.
Galderma. Data on file. MA-48544 Subject satisfaction (GAIS) – NASHA and OBT Fillers. 2021.
Kablik J, et al. Comparative physical properties of HA dermal fillers. Dermatol Surg. 2009; 35, 302–312. doi: 10.1111/j.1524-4725.2008.01046.x.
Edsman K, et al. Gel properties of hyaluronic acid dermal fillers. Dermatol Surg. 2012;38:1170–1179. doi: 10.1111/j.1524-4725.2012.02472.x.
Solish N, et al. Dynamics of hyaluronic acid fillers formulated to maintain natural facial expression. J Cosmet Dermatol. 2019;18(3):738-746. doi: 10.1111/jocd.12961.
Philipp‐Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. J Cosmet Dermatol. 2020;19(7):1600-1606. doi: 10.1111/jocd.1320
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915734207/en/
Permalink
https://www.aetoswire.com/en/news/1609202657354
Contacts
For further information:
Christian Marcoux, M.Sc.
Chief Communications Officer
christian.marcoux@galderma.com
+41 76 315 26 50
Richard Harbinson
Corporate Communications Director
richard.harbinson@galderma.com
+41 76 210 60 62
Céline Buguet
Franchises and R&D Communications Director
celine.buguet@galderma.com
+41 76 249 90 87
Emil Ivanov
Head of Strategy, Investor Relations, and ESG
emil.ivanov@galderma.com
+41 21 642 78 12
Jessica Cohen
Investor Relations and Strategy Director
jessica.cohen@galderma.com
+41 21 642 76 43
Thursday, September 17, 2026
Schneider Electric Concludes Innovation Summit Middle East & Africa, Highlights Energy Intelligence as the Next Phase of the Energy Transition
Abu Dhabi, United Arab Emirates -
As AI, electrification and industrial expansion reshape energy demand across the Middle East and Africa, Schneider Electric today concluded Innovation Summit Middle East & Africa by positioning energy intelligence as the next phase of the energy transition - where infrastructure becomes more connected, resilient and software-defined.
Held at ADNEC in Abu Dhabi, the two-day summit convened over 2,500 attendees, including government leaders, industry analysts, customers, partners, students, and media, under the theme ‘Advancing Energy Tech to Power Intelligence and Resilience.’
Industry leaders explored how electrification, AI-ready data centers, cybersecurity, and digital innovation are reshaping energy systems. Day one featured keynotes from H. E. Abdullah bin Touq Al Marri, UAE Cabinet Member and Minister of Economy and Tourism, and Schneider Electric CEO Olivier Blum, in the presence of H.E. Marie Audouard, Ambassador Extraordinary and Plenipotentiary of the French Republic to the UAE. The summit also featured the launch of the Innovation Hub, the Data Cube, and Olivier Blum’s address on “The Era of Intelligence.”
“We’re entering an Era of Intelligence in which AI is becoming embedded in the physical economy. AI may be digital, but it runs on electricity and depends on the physical systems beneath it,” said Olivier Blum, CEO of Schneider Electric. “As an Energy Technology Partner, we help customers connect energy and operations through data, software, AI and automation, turning intelligence into action to improve performance, resilience and competitiveness. The scale of this shift is clear in the Middle East and Africa, where governments and businesses are investing in energy and digital infrastructure to support industrial transformation and long-term growth.”
The summit also featured the release of the company’s 2026 Industrial AI in CPG Study for the UAE, which found that 59% of UAE manufacturers expect transformational AI adoption by 2030, compared with 42.2% globally. Walid Sheta, President, MEA Zone, said, “As our region’s manufacturers move faster and more confidently on industrial AI than anywhere else, it’s our responsibility to make sure that confidence is well-founded. Cybersecurity, resilience, and return on AI investment are the concerns we hear about most often from customers, and rightly so.”
Schneider Electric reaffirmed its commitment to collaborating with governments, customers, and partners to accelerate intelligent, resilient energy infrastructure.
Permalink
https://www.aetoswire.com/en/news/1609202657358
Contacts
Press contact:
Mohammed Abdulla
mabdulla@apcoworldwide.com
www.se.com
Wednesday, September 16, 2026
Rubedo Life Sciences Announces Clinical Study to Treat Hair Loss with GPX4 Modulator RLS-1496, First Human Ex Vivo Evidence Demonstrates Robust Hair Follicle Growth
MOUNTAIN VIEW, Calif. - Wednesday, 16. September 2026 AETOSWire
AGA clinical trial to begin in Fall 2026 led by David Pariser, MD, FACP, FAAD, former President of the American Academy of Dermatology and Principal Investigator in more than 450 dermatology clinical trials
Rubedo’s RLS-1496, the first and only GPX4 modulator currently in clinical trials, demonstrates superior hair follicle restoration in human ex vivo androgenetic alopecia (AGA) model, matching or outperforming finasteride; findings consistent with dual SenoAdaptive mechanism that activates dormant hair follicle
(BUSINESS WIRE) -- Rubedo Life Sciences, Inc. (Rubedo) today announced a new clinical study of investigational RLS-1496 in patients with androgenetic alopecia (AGA), beginning October 2026, with initial data expected in the first half of 2027. The study marks the first-ever clinical evaluation of a GPX4 modulator in hair loss, extending the program that established RLS-1496 as the world’s first GPX4 modulator to enter human clinical trials of any kind.
RLS-1496 has already demonstrated efficacy in clinical trials for actinic keratoses and aging skin, and other skin conditions such as psoriasis and atopic dermatitis, generating novel human evidence demonstrating the dual SenoAdaptive mechanism that clears pathologic senescent cells and promotes a redox reset by modulating NRF2 pathways in stressed aged cells, including stem and progenitor cells. Ex vivo studies on a human hair follicles AGA model resulted in the restoration of hair follicle growth, as depicted in the image above.
In an independent ex vivo human AGA model — conducted using intact human hair follicles from male patients with AGA, challenged with dihydrotestosterone (DHT) to replicate the follicular miniaturization environment seen in AGA patients — RLS‑1496 demonstrated statistically and highly statistically significant increases in hair follicle elongation compared to vehicle control at 2 doses, respectively, with the highest dose showing a numerically greater trend in mean elongation than finasteride.
Hair follicle elongation at Day 6 was greater with RLS-1496 versus vehicle across all doses, with the strongest effect at the highest concentration — directionally outperforming standard-of-care finasteride
The pattern is consistent with rescue of the anagen (active growth) phase, when targeting senescent cells from the follicular niche allows stem cell reactivation from the dormant state and the follicle to resume its natural growth program
“The senescent cell biology underlying hair follicle aging is compelling, deeply consistent with what we have seen across our RLS-1496 program, and vastly underexplored as a therapeutic target,” said Rubedo Chief Executive Officer Frederick Beddingfield III, MD, PhD, FAAD. “For the first time, we are bringing a medicine into the clinic designed to clear the aged cells at the root of stem cell dormancy and follicular miniaturization. We are proud to do so in partnership with Dr. Pariser, and we are moving with the same urgency that made RLS-1496 the world’s first GPX4 modulator in human trials.”
AGA is the most prevalent form of hair loss globally, affecting approximately 50 million men and 30 million women in the U.S. alone; however, the treatment landscape has seen no genuinely new FDA-approved approaches in nearly 30 years.2 The global AGA market, valued at $3.2 billion in 2025 and projected to reach $6.8 billion by 2035, is defined by two therapies — minoxidil and finasteride — that slow the hormonal signals that cause hair follicles to progressively shrink and degenerate, a process known as follicular miniaturization. Follicular miniaturization is the biological hallmark of AGA, in which each successive growth cycle produces a thinner, shorter hair until the follicle can no longer produce visible hair. Neither therapy addresses the senescent — aged and dysfunctional — cells now understood to accumulate within the follicular niche and drive this miniaturization at the cellular level.3,4,5
Unlike existing therapies that target secondary hormonal causes of hair loss, RLS-1496 is designed to act on the primary cellular aging mechanism: the accumulation of senescent and stressed dermal papilla cells that actively suppress stem cells, follicular regeneration, and drive progressive miniaturization. By targeting these cells with selective elimination or functional restoration, depending on the cell state, RLS-1496, a first-in-class SenoAdaptive Drug, aims to remove the cellular brake on follicular regeneration itself.3,4,5,6
Rubedo Co-Founder and Chief Scientific Officer Marco Quarta, PhD, will present the ex vivo data, along with additional RLS-1496 data, at the 13th Annual Aging Research & Drug Discovery (ARDD) Meeting at Harvard University, October 1–3, 2026 — the world’s largest dedicated longevity science conference. The presentation marks the first time a GPX4 modulator program in hair loss will be presented at a major longevity science conference.
Dr. Quarta said, “RLS-1496 appears to act at several convergent points in the AGA disease cascade — where we believe it acts by clearing senescent cells, suppressing follicular regeneration, reducing inflammatory SASP signaling, while also modulating NRF2 pathways and activating Wnt/β-catenin pathways governing anagen re-entry. To our knowledge, no approved AGA therapy operates at this level of biology.”
Rubedo’s proprietary ALEMBIC™ spatial transcriptomics applied to patient hair follicle biopsies identified senescence markers and transcriptomic signals consistent with activation of the follicular regenerative cascade, including the expansion of hair follicle progenitors, and downregulation of key drivers of the follicle regression phase — providing human clinical evidence that RLS-1496’s effects on senescent cell biology extend to hair follicle tissue. In preclinical animal studies, RLS-1496 also achieved approximately 32% greater hair regrowth versus vehicle.1,6,7
“The preliminary data we have seen with RLS-1496 are scientifically intriguing and warranted clinical evaluation,” said Dr. Pariser, Professor of Dermatology at Eastern Virginia Medical School and Principal Investigator of Virginia Clinical Research, Inc., who will be leading the RLS-1496 hair loss clinical trial. “The senescence biology underlying AGA is increasingly well-supported in the published literature, and RLS-1496 represents a genuinely novel approach to it. I look forward to seeing what the data show in patients given the ongoing unmet need.”
About RLS-1496 and GPX4 Modulation
Rubedo’s lead candidate RLS-1496, being developed for topical and oral administration, is a first-in-class, disease-modifying GPX4 modulator selectively targeting pathologic senescent and other stressed, aging cells that drive chronic, age-dependent diseases. These include immunology and inflammation (I&I), dermatology and skin aging, hair loss, metabolic syndrome (obesity, diabetes, liver fibrosis), sarcopenia, and neurodegenerative disease.
In certain pathologic cells, aging is associated with an imbalance in GPX4. Modulation of GPX4 sensitizes cells to ferroptosis, which is a type of programmed cell death and is believed to be an Achilles heel of senescent cells. By modulating GPX4 in ferroptosis-sensitive senescent “aged” cells, RLS-1496 may be able to clear these cells to fight disease and also support healthy cells to function properly and restore tissue homeostasis. Beyond its targeted senolytic function in triggering selective ferroptosis within pathological senescent cells, RLS-1496 can also act as a restorative modulator that induces a vital ‘redox-reset’ through a controlled hormetic response in stressed neighboring cells, effectively clearing the source of chronic inflammation while actively re-establishing healthy tissue homeostasis. This dual-action mechanism represents a novel drug category—Adaptive SenoTherapeutics.
RLS-1496 uses Rubedo’s proprietary, AI-driven drug discovery platform ALEMBIC™, which identifies targets within pathologic senescent cells and develops selective cellular rejuvenation medicines for these targets.
About Rubedo Life Sciences
Rubedo Life Sciences is a clinical-stage biotech developing a broad portfolio of innovative selective cellular rejuvenation medicines targeting aging cells that drive chronic age-related diseases. Our proprietary AI-driven ALEMBIC™ drug discovery platform is developing novel first-in-class small molecules to selectively target pathologic and senescent cells, which play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic, and other chronic disorders, including hair loss. Our lead drug candidate – RLS-1496, a potential first-in-class disease-modifying GPX4 modulator – is currently in Phase I clinical trials. The Rubedo leadership team is composed of industry leaders and early pioneers in chemistry, AI technology, longevity science, and life sciences, with expertise in drug development and commercialization from both large pharmaceutical and leading biotechnology companies. The company is headquartered in Mountain View, CA, USA, and has offices in Milan, Italy. For additional information, visit www.rubedolife.com.
References
Rubedo Life Sciences. RLS-1496 demonstrates hair follicle elongation in a DHT-challenged ex vivo androgenetic alopecia model. Data on file. 2026.
Global Market Insights. Androgenetic Alopecia Treatment Market Size, Share & Trends Analysis Report. 2026
Bahta AW, Farjo N, Farjo B, Philpott MP. Premature Senescence of Balding Dermal Papilla Cells In Vitro Is Associated with p16(INK4a) Expression. Journal of Investigative Dermatology2008;128(5):1088-1094. doi: 10.1038/sj.jid.5701147
Yang YC, Fu HC, Wu CY, Wei KT, Huang KE, Kang HY. Androgen Receptor Accelerates Premature Senescence of Human Dermal Papilla Cells in Association with DNA Damage. PLoS ONE2013;8(11): e79434. doi: 10.1371/journal.pone.0079434
Upton JH, Hannen RF, Bahta AW, Farjo N, Farjo B, Philpott MP. Oxidative Stress-Associated Senescence in Dermal Papilla Cells of Men with Androgenetic Alopecia. Journal of Investigative Dermatology 2015;135(5):1244-1252. doi: 10.1038/jid.2015.28
Pappalardo A, Kim JY, Abaci HE, Christiano AM. Restoration of hair follicle inductive properties by depletion of senescent cells. Aging Cell2024;24: e14353. doi: 10.1111/acel.14353
Rubedo Life Sciences. RLS-1496 achieves 32% greater hair regrowth versus vehicle in preclinical animal studies. Data on file. 2026.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260916811892/en/
Permalink
https://www.aetoswire.com/en/news/1609202657361
Contacts
Investor Contact: Ali Siam, Chief Business Officer alisiam@rubedolife.com | 781-974-9559
Media Contact: Peter Collins, TogoRun p.collins@togorun.com | 908-499-1200
NetApp and Tampa Bay Buccaneers Partner to Enable Data-Driven Operational Excellence
New sponsorship expands NetApp’s presence across the NFL, delivering trusted data, intelligence, and the ability to perform in critical moments
(BUSINESS WIRE)--NetApp® (NASDAQ: NTAP), the Intelligent Data Infrastructure company, today announced that they have been named an Official Partner of the Tampa Bay Buccaneers. This new relationship builds on NetApp’s status as the Official Intelligent Data Infrastructure Partner of the NFL, helping the league and its teams quickly and confidently access, manage, and activate their data. The Buccaneers will leverage NetApp technology to support the experience for Buccaneers fans in the stadium on game days and beyond.
“NetApp will serve as a trusted technology partner that will help us elevate the customer experience for all Buccaneers fans,” said Buccaneers Chief Commercial Officer Atul Khosla. “Reliable and secure access to data plays an essential role in the overall game day experience at Raymond James Stadium. NetApp’s industry-leading intelligent data infrastructure will help us deliver a more seamless and connected experience for our Krewe at games and across the digital platforms that we use.”
This partnership launches following the Buccaneers first regular 2026 season game against the Cincinnati Bengals on September 13. The partnership expands NetApp’s relationship with the NFL as the league’s Official Intelligent Data Infrastructure Partner, helping to securely manage, protect, and activate the data behind the league’s operations. Across the NFL, NetApp technology supports demanding real-world workloads, including the storage and availability of game day video used by NFL football operations and club football operations teams. This collaboration has demonstrated how the right infrastructure can help complex, data-intensive organizations operate more efficiently and resiliently.
By using NetApp Keystone, a flexible and simple subscription-based service that adapts to changing business needs, the Buccaneers can accelerate data workloads with industry-leading performance, intelligent data management, and high availability across data centers and cloud environments. The NetApp Platform delivers built-in data security that autonomously detects threats and enables rapid recovery.
“Successful teams achieve meaningful results long before game day by bringing together the right people, trusted data, sound decisions, and disciplined execution,” said Gabie Boko, Chief Marketing Officer at NetApp. “Elite sports show what organizations can accomplish when their people can turn information into confident action. As a Proud Partner of the Tampa Bay Buccaneers, we’re celebrating the preparation, trust, and teamwork that sustain excellence and the Intelligent Data Infrastructure that helps make it possible.”
Additional Resources
NetApp and the NFL Team Up with Intelligent Data Infrastructure
The Unseen MVP of the NFL Season
NetApp Named Presenting Partner of 2026 NFL Madrid Game
NetApp Data Platform Powers Data Operations for Super Bowl LX
About the Tampa Bay Buccaneers
The Tampa Bay Buccaneers are in their 51st season as members of the National Football League and compete in the National Football Conference’s South Division. They were purchased by the late Malcolm Glazer in 1995 and are currently owned by the Glazer Family. Established in 1976, the Buccaneers have totaled 10 division titles, two conference championships and two Super Bowl Championships, including Super Bowl LV that was played on their home field at Raymond James Stadium. The Buccaneers have also been leaders in the NFL in fan engagement, earning a record 12 consecutive No. 1 rankings in overall customer satisfaction in the league’s annual Voice of the Fan survey. Additionally, the franchise is very active in the community, with the Tampa Bay Buccaneers Foundation, the Glazer Vision Foundation and the Glazer Family Foundation. For more information, visit www.buccaneers.com.
About NetApp
For more than three decades, NetApp has helped the world’s leading organizations navigate change – from the rise of enterprise storage to the intelligent era defined by data and AI. Today, NetApp is the Intelligent Data Infrastructure company, helping customers turn data into a catalyst for innovation, resilience, and growth.
At the heart of that infrastructure is the NetApp data platform – the unified, enterprise-grade, intelligent foundation that connects, protects, and activates data across every cloud, workload, and environment. Built on the proven power of NetApp ONTAP, our leading data management software and OS, and enhanced by automation through the AI Data Engine and AFX, it delivers observability, resilience, and intelligence at scale.
Disaggregated by design, the NetApp data platform separates storage, services, and control so enterprises can modernize faster, scale efficiently, and innovate without lock-in. As the only enterprise storage platform natively embedded in the world’s largest clouds, it gives organizations the freedom to run any workload anywhere with consistent performance, governance, and protection.
With NetApp, data is always ready – ready to defend against threats, ready to power AI, and ready to drive the next breakthrough. That’s why the world’s most forward-thinking enterprises trust NetApp to turn intelligence into advantage.
Learn more at www.netapp.com or follow us on X, LinkedIn, Facebook, and Instagram.
NETAPP, the NETAPP logo, and the marks listed at www.netapp.com/TM are trademarks of NetApp, Inc. Other company and product names may be trademarks of their respective owners.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260916768662/en/
Permalink
https://aetoswire.com/en/news/1609202657360
Contacts
Media Contact:
Kenya Hayes
NetApp
kenya.hayes@netapp.com
Investor Contact:
Kris Newton
NetApp
kris.newton@netapp.com
The Opening of Jayasom Wellness Resort Advancing AMAALA’s Wellness Vision
RIYADH, Saudi Arabia -
The latest addition to AMAALA’s wellness ecosystem integrates evidence-based practices with Arab and Eastern healing practices complemented by personalized wellness programs
(BUSINESS WIRE)--Red Sea Global (RSG), the regenerative tourism developer, has opened Jayasom Wellness Resort AMAALA, bringing a distinctive holistic health offering to the destination.
Designed by Heah & Co., with interiors by Studio Carter, Jayasom Wellness Resort AMAALA is located on Triple Bay’s largest cove and comprises 153 keys alongside 24 residences. The resort forms part of AMAALA’s secluded wellness core on the Red Sea coast, where nature and hospitality come together in a setting designed for reflection and renewal.
“As we launch the first Jayasom globally, we are bringing a new dimension to AMAALA’s wellness offering. Its dedicated, all-inclusive wellness retreats combine contemporary, evidence-based practices with Arab and Eastern healing traditions. Its personalized approach complements our ambition for AMAALA to become the world’s most comprehensive wellness destination supporting guests on their long-term health journeys in an exceptional natural environment,” said John Pagano, Group CEO of Red Sea Global.
The resort’s wellness philosophy brings together Arab and Eastern healing traditions alongside contemporary evidence-based practices, reflecting centuries of knowledge exchange across cultures, including contributions from pioneering scholars such as Ibn Sina (Avicenna). The offering spans holistic health, fitness, physiotherapy, nutrition, spa and beauty, supported by consultations, movement and daily activities. Each guest journey is tailored to individual goals including women’s health, couples and family wellbeing, as well as health, weight and lifestyle reset.
Nutrition is an integral part of the Jayasom Wellness Resort AMAALA experience, with a collection of eight dining venues designed to support balanced lifestyles. The resort's restaurants and cafés offer a diverse range of cuisines inspired by regional and international traditions, with an emphasis on fresh, seasonal ingredients and nutritious dishes. Complementing the dining offer are interactive culinary experiences and specialty concepts that encourage guests to explore the role of food in healthy living.
The resort is divided into an adults-only wellness offering and a dedicated experience for families. The adult-only zone provides a sanctuary focused on holistic therapies, physiotherapy, fitness and Pilates, while the family experiences feature age-specific facilities and activities designed to support connection, movement and healthy habits.
The Jayasom Residences comprise a limited collection of two- to four-bedroom beachfront villas, with private pools and expansive sea-facing terraces. Located adjacent to the resort, residents enjoy exclusive privileges such as complimentary wellness retreats, preferred access to treatments and dining, and invitations to Jayasom events worldwide.
Nestled between the Red Sea and the dramatic Tabuk mountains, the resort is surrounded by coastal landscapes providing opportunities for land and water-based activities. This includes hiking, trail running, cycling, kayaking, stand-up paddleboarding, snorkeling and diving.
Along with the rest of the destination, Jayasom Wellness Resort AMAALA is fully powered by solar energy. It also supports the destination’s ambition to achieve a 30% net conservation gain by 2040.
Jayasom AMAALA is the seventh resort to open at AMAALA, marking another milestone in the destination’s phased delivery. In the coming months, a further two resorts will join a growing portfolio of world-class hospitality brands, alongside branded residences, integrated wellness facilities, a marina, curated retail, a marine life experiential institute and destination dining.
About Red Sea Global
Red Sea Global (RSG) is a vertically integrated real estate developer with a diverse portfolio across tourism, residential, experiences, infrastructure, transport, healthcare, and services. This includes the luxury regenerative tourism destinations The Red Sea, which began welcoming guests in 2023, and AMAALA, which welcomed its first guests in 2026.
A third destination, Thuwal Private Retreat, opened in 2024. RSG was also entrusted with development works at AlWajh International Airport, focused on upgrading the terminal and infrastructure.
RSG is a PIF company and a cornerstone of Saudi Arabia’s ambition to diversify its economy. Across its growing portfolio of destinations, subsidiaries, and businesses, RSG seeks to lead the world toward a more sustainable future, showing how responsible development can uplift communities, drive economies, and enhance the environment.
About AMAALA
AMAALA is an unparalleled ultra-luxury wellness destination along the northwestern coast of the Red Sea in Saudi Arabia. Seamlessly blending sea, sun, sports, arts, and culture for an exceptional experience, it is one of the world’s most anticipated destinations developed by Red Sea Global (RSG) with regeneration at its core.
AMAALA officially opened its first resort in summer of 2026, with more than 1,600 hotel rooms set to open across nine different resorts complemented by high-end retail and fine dining experiences upon completion. The destination’s state-of-the-art wellness and spa facilities will offer a comprehensive array of multi-generational programs, services, and various therapies, customized by practitioners and centers pioneering in various medical and wellness fields for a more personalized wellness journey.
Influenced by AMAALA’s natural beauty and the purity of the Red Sea, the destination is where sustainability meets luxury. The aim of AMAALA is to offer the most comprehensive health and wellness experience that will help improve the wellbeing of its guests and community, helping them flourish and thrive.
Two of AMAALA’s hallmark features include Corallium Marine Life Institute, an educational and scientific research center, and the AMAALA Yacht Club, destined to become an international hub for luxury yachting.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260916231950/en/
Permalink
https://aetoswire.com/en/news/1609202657362
Contacts
For more information, please contact:
Arwa Alsantli, Manager - Public Relations
+966 56 616 6017
Arwa.Alsantli@RedSeaGlobal.com
iQmetrix to Deliver 2026 Telecom Industry Address and Product Announcements, Unveiling the Next Wave of Intelligent Commerce
VANCOUVER, British Columbia - Tuesday, 15. September 2026 AETOSWire Print
iQmetrix's annual industry briefing goes global on October 28, pairing a year of worldwide market intelligence with the company's outlook on AI-native commerce and a first look at what's next for its Intelligent Commerce Operating System
(BUSINESS WIRE)--iQmetrix, the global provider of Intelligent Commerce Operating Systems for telecom, today opened registration for the 2026 Telecom Industry Address and Product Announcements, taking place Wednesday, October 28, 2026. For the first time in the event's history, iQmetrix will run two dedicated virtual sessions: one built specifically for European audiences, alongside its long-running North American event. Both are free to attend.
Now in its seventh year, the Industry Address has become the telecom channel's annual checkpoint: an unfiltered read on where the market is heading, delivered by a company that sits at the intersection of telcos, retailers, and the partners who serve them. The 2026 edition draws on a year of research and direct conversations across international markets.
"We spend the year listening — to telcos, to retailers, to the partners building alongside us, in a dozen different markets," said Megan Howse, Senior Vice President, Marketing at iQmetrix. "The Telecom Industry Address is where all of that turns into something the industry can actually use. Adding a European session means we're no longer asking half our audience to take the North American view and translate it."
The 90-minute program runs in two parts. The first covers the trends, pressures, and openings shaping telecom commerce globally. The second is iQmetrix's annual product announcement, including an early look at what is coming next for the Intelligent Commerce Operating System — the category iQmetrix has defined around one orchestrated system connecting point of sale, ecommerce, inventory, activations, and customer journeys, with AI embedded in how the system runs rather than layered on top.
The event is open to the wider industry: telcos, retailers, repair providers, device and accessory manufacturers, distributors, industry media, and the broader telecom ecosystem. Attendees will leave with a clearer read on where the market is moving and practical direction for their commerce strategy in the year ahead.
Session details — Wednesday, October 28, 2026
Europe session: 1:00 p.m. UK / 2:00 p.m. CET / 9:00 a.m. ET / 7:00 a.m. MT
North America session: 12:00 p.m. ET / 10:00 a.m. MT / 9:00 a.m. PT / 5:00 p.m. CET
Both sessions cover the same content; attendees need only join the one that suits their schedule.
Registration is now open here. A recording will be sent to everyone who registers, whether or not they attend live.
About iQmetrix
iQmetrix is the global provider of Intelligent Commerce Operating Systems for telecom. It replaces fragmented legacy stacks with a modern, modular layer that orchestrates telcos, retailers, and OEMs into one intelligent flow across channels and markets. The result is less complexity, lower cost, and the speed to move ahead.
For 27years, iQmetrix has helped the leading brands in telecom grow by providing best-in-class software, services, and expertise. Its solutions powered $17 billion in sales last year, handling nearly 53 million invoices and more than 28 million activations, and are used by more than 370,000 telecom retail professionals across almost 1,000 clients. iQmetrix is a privately held software-as-a-service (SaaS) company with employees in Canada, the U.S., India, and Europe. For more information, visit www.iqmetrix.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260914992633/en/
Permalink
https://www.aetoswire.com/en/news/1509202657312
Contacts
Media Contact
media@iqmetrix.com
Chiesi Appoints David Khougazian as Group Chief Executive Officer to Lead the Next Phase of Innovation-Driven Growth
PARMA, Italy -
Highlights:
David Khougazian appointed Group Chief Executive Officer to lead Chiesi's next phase of innovation-driven growth, effective 15 October 2026.
Bringing over 25 years of international healthcare leadership experience and a strong track record in innovation and transformation, David joins Chiesi from Flagship Pioneering.
(BUSINESS WIRE) -- Chiesi Group (Chiesi) today announced the appointment of David Khougazian as Group Chief Executive Officer (CEO), effective 15 October 2026.
David joins Chiesi following a distinguished international career spanning more than 25 years across the global healthcare and life sciences sectors. Most recently, he served as Executive Partner, Growth, and Head of Global Engagement at Flagship Pioneering, where he supported the growth and development of science-driven healthcare companies and worked closely with leadership teams on long-term value creation, partnerships, financing and organizational development.
Following a thorough selection process led by the Board of Directors, David will succeed Interim Group CEO Jean-Marc Bellemin, who has successfully led the Group since 15 May 2026, while also continuing in his permanent role as Group CFO.
Maria Paola Chiesi, Chiesi Group Chair, commented: “We are delighted to welcome David to Chiesi at a time of strong momentum for the company. Innovation has always been at the heart of Chiesi's mission and long-term vision. David's appointment reflects our ambition to accelerate this journey and strengthen Chiesi’s ability to innovate in a healthcare environment that is changing faster than ever. He brings a unique combination of global healthcare leadership, operational experience and exposure to some of the most dynamic areas of biotech innovation, which makes him exceptionally well positioned to guide Chiesi through this next chapter.
On behalf of the Board, I would like to express my sincere gratitude to Jean-Marc Bellemin for his commitment and stewardship during this transition period. I would also like to thank the entire Group Executive Leadership Team for their dedication and collective leadership, which have been instrumental in maintaining the Group's focus and preparing the organization for the next steps."
David Khougazian commented: “I am honored and excited to join Chiesi, a company widely recognized for its strong values, scientific excellence, entrepreneurial mindset and commitment to patients. The healthcare landscape is evolving rapidly, creating extraordinary opportunities to advance innovation and transform patient outcomes. Chiesi has built an impressive foundation, combining scientific expertise and a clear commitment to sustainable growth across generations.
I look forward to working alongside Chiesi colleagues around the world to further strengthen the Group's innovation capabilities, advance its pipeline and partnerships, and create lasting value for patients, healthcare systems and society.”
Chiesi remains firmly committed to executing its patient-centric strategy, advancing innovation across its therapeutic areas, and delivering sustainable growth for the benefit of patients, healthcare systems, communities and the planet.
About Chiesi Group
Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment.
By adopting the legal form of Benefit Corporation in Italy, the US, France and Colombia, Chiesi’s commitment to creating shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, Chiesi meets verified standards for social and environmental business practices. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development center in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit www.chiesi.com or the website of your local Chiesi affiliate.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260915411388/en/
Permalink
https://www.aetoswire.com/en/news/1509202657328
Contacts
Press Info:
Anna Bonisoli Alquati, Head of Global External Communications: mediarelations@chiesi.com
Michela Lijoi, Global External Communications Sr. Manager: mobile +39 328.6353044, e-mail: m.lijoi@chiesi.com
Davide Paterlini, Global External Communications Sr. Manager: mobile +39 345.7983132, e-mail: d.paterlini@chiesi.com
Subscribe to:
Posts (Atom)